COVID-19 in low-tolerance border quarantine systems: Impact of the Delta variant of SARS-CoV-2.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
08 Apr 2022
08 Apr 2022
Historique:
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
9
4
2022
Statut:
ppublish
Résumé
In controlling transmission of coronavirus disease 2019 (COVID-19), the effectiveness of border quarantine strategies is a key concern for jurisdictions in which the local prevalence of disease and immunity is low. In settings like this such as China, Australia, and New Zealand, rare outbreak events can lead to escalating epidemics and trigger the imposition of large-scale lockdown policies. Here, we develop and apply an individual-based model of COVID-19 to simulate case importation from managed quarantine under various vaccination scenarios. We then use the output of the individual-based model as input to a branching process model to assess community transmission risk. For parameters corresponding to the Delta variant, our results demonstrate that vaccination effectively counteracts the pathogen's increased infectiousness. To prevent outbreaks, heightened vaccination in border quarantine systems must be combined with mass vaccination. The ultimate success of these programs will depend sensitively on the efficacy of vaccines against viral transmission.
Identifiants
pubmed: 35394833
doi: 10.1126/sciadv.abm3624
pmc: PMC8993115
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabm3624Références
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
Transp Policy (Oxf). 2020 Sep;96:76-93
pubmed: 32834680
J R Soc Interface. 2021 Apr;18(177):20210063
pubmed: 33878278
Transp Policy (Oxf). 2021 Sep;110:273-280
pubmed: 36567696
Vaccine. 2022 Dec 5;40(51):7360-7369
pubmed: 34872796
Lancet Reg Health West Pac. 2020 Nov;4:100044
pubmed: 34013216
J R Soc Interface. 2021 Jan;18(174):20200657
pubmed: 33404371
Euro Surveill. 2022 Mar;27(10):
pubmed: 35272744
Nat Hum Behav. 2020 Dec;4(12):1303-1312
pubmed: 33199859
Lancet Reg Health West Pac. 2021 Sep;14:100224
pubmed: 34345875
Science. 2021 Dec 17;374(6574):eabl9551
pubmed: 34726481
Med J Aust. 2020 Sep;213(5):198-200.e1
pubmed: 32789868
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7
pubmed: 34826623
BMJ. 2021 Aug 18;374:n2050
pubmed: 34407982
BMC Med. 2021 Apr 27;19(1):106
pubmed: 33902581
China CDC Wkly. 2021 Jul 2;3(27):584-586
pubmed: 34594941
BMJ. 2021 Apr 1;373:n861
pubmed: 33795260
Elife. 2020 Feb 24;9:
pubmed: 32091395
Nat Hum Behav. 2020 Jun;4(6):577-587
pubmed: 32493967
Elife. 2021 Feb 05;10:
pubmed: 33543709
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1059-1062
pubmed: 34351882
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7504-7509
pubmed: 32170017
J Travel Med. 2020 May 18;27(3):
pubmed: 32181488